ANAVEX
Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.
Anavex2-73By alessandroFebruary 11, 2016
ACTRIMS Forum 2016, New Orleans, Louisiana Robert P. Lisak M.D., Liljana Nedelkoska, Joyce A. Benjamins, Ph.D., Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan View Poster
Multiple sclerosis
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
Events, News Releases, PIPELINEBy alessandroOctober 27, 2017
ANAVEX®2-73 Shown to Protect and Repair Myelin Forming Cells NEW YORK, NY – October 27, 2017 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…
Anavex Life Sciences Reports Fiscal 2016 Financial Results
News Releases, PIPELINEBy alessandroDecember 12, 2016
Conference Call and Webcast Today at 4:30 p.m. ET to Discuss Financial Results and Clinical Progress NEW YORK – December 12, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system…
Anavex Compound to be Tested in Biogen Neurological Protection Model
News Releases, PIPELINEBy alessandroSeptember 28, 2016
NEW YORK, NY, September 28, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that it has signed a material…
ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016
News ReleasesBy alessandroFebruary 17, 2016
– Preclinical data relevant for multiple sclerosis and other neurodegenerative diseases – NEW YORK, NY – February 17, 2016 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various…
ANAVEX
ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2017 All Rights Reserved
Another Biogen video Check out @biogenms’s Tweet:
